Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Anguilla Business Daily.
Press releases published on August 12, 2025
Highwoods Recasts Term Loan
GlobeNewswire
·
August 12, 2025
RALEIGH, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Highwoods Properties, Inc. (NYSE:HIW) has executed a recast of a $200 million unsecured bank term loan by extending the maturity date from May 2026 to January 2029. The term can be extended for two …
Playboy Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 12, 2025
Q2 Revenue of $28.1 Million, up 13% Year-over-Year; Net Loss of $7.7 Million, an Improvement of $9.0 Million; Adjusted EBITDA of $3.5 Million, an Improvement of $6.4 Million LOS ANGELES, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Playboy, Inc. (NASDAQ: PLBY) (the “ …
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 12, 2025
Topline data for registrational Phase 2 trial of KYV-101 in stiff person syndrome (SPS) and BLA submission anticipated in 1H 2026 Registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) to include ~60 patients with enrollment to initiate by year-end …
Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
GlobeNewswire
·
August 12, 2025
MZE782 Phase 1 Trial in Healthy Volunteers to Provide Proof of Mechanism Data for Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) Expected in Q3 2025 MZE829 Phase 2 HORIZON Trial Actively Enrolling Patients with APOL1-Mediated Kidney Disease; …
Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
GlobeNewswire
·
August 12, 2025
Second quarter 2025 revenues were $15.0 million Emrosi™ net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June 2025 Company to hold conference call today at 4:30 p.m. …
Erasca Reports Second Quarter 2025 Business Updates and Financial Results
GlobeNewswire
·
August 12, 2025
Efficient execution accelerated clinical entry of pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Phase 1 monotherapy data for RAS-targeting franchise expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable …
Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights
GlobeNewswire
·
August 12, 2025
Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025 Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif …
Editas Medicine Announces Second Quarter 2025 Results and Business Updates
GlobeNewswire
·
August 12, 2025
Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026 First IND/CTA accepted for CD19 HD Allo CAR T program as part of collaboration with Bristol Myers Squibb, …
IZEA Reports Q2 2025 Revenue of $9.1 Million
GlobeNewswire
·
August 12, 2025
Reporting $1.2 Million in Net Income, Achieving $0.07 per Share, Positive Cash from Operations ORLANDO, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- IZEA Worldwide, Inc. (NASDAQ: IZEA), a leading influencer marketing company that makes Creator Economy solutions …
Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
GlobeNewswire
·
August 12, 2025
First patient treated with FT819 off-the-shelf CAR T-cell product candidate following fludarabine-free conditioning for severe lupus nephritis demonstrated durability of response with drug-free definition of remission in systemic lupus erythematosus (DORIS …
Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 12, 2025
– Company reports $12.7 million in revenue in Q2’25, consisting primarily of $4.5 million in YCANTH® revenue, net, reflecting sequential growth of 32.5% over Q1’25 and $8.0 million in milestone revenue from Torii Pharmaceutical – – Completed Successful …
Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update
GlobeNewswire
·
August 12, 2025
PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC) Spero, along with its development partner, GSK, plans to …
374Water Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 12, 2025
Ongoing Deployments and Successful Waste Destruction Demonstrations Showcase AirSCWO Technology Across Municipal, Federal and Industrial Market Verticals DURHAM, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- 374Water Inc. (NASDAQ: SCWO) ("374Water" or the " …
Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 12, 2025
– Positive ENLIGHTEN 2 Phase 3 results announced in June 2025 propel business activities in manufacturing, regulatory strategy and ENLIGHTEN clinical dataset analysis to advance path forward for LYR-210 for treatment of chronic rhinosinusitis (CRS) – – …
Compass Therapeutics Announces Proposed Public Offering
GlobeNewswire
·
August 12, 2025
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today …
ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
GlobeNewswire
·
August 12, 2025
FDA confirmed at a July 2025 Type B meeting and in the subsequent meeting minutes that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with type 2 diabetes and advanced CKD; FDA also confirmed that the …
FormFactor, Inc. Announces CFO Transition
GlobeNewswire
·
August 12, 2025
LIVERMORE, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- FormFactor, Inc. (Nasdaq: FORM) (the “Company” or “FormFactor”) today announced that Aric McKinnis, currently its Vice President and Corporate Controller, has been appointed to serve as the Company’s new …
WOOF INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Petco Health and Wellness Company, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
GlobeNewswire
·
August 12, 2025
NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz …
TSLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Tesla, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
GlobeNewswire
·
August 12, 2025
NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz …
TEM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
GlobeNewswire
·
August 12, 2025
NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz …